Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) had Return on Tangible Equity of -137.28% for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
-- |
|
$-5.06M |
|
-- |
|
-- |
|
$5.09M |
|
$-5.09M |
|
$0.03M |
|
$-5.06M |
|
$-5.06M |
|
$-5.06M |
|
$-5.06M |
|
$-5.06M |
|
$-5.06M |
|
$-5.09M |
|
$-5.09M |
|
8.05M |
|
8.05M |
|
$-0.64 |
|
$-0.64 |
|
| Balance Sheet Financials | |
$5.23M |
|
$0.15M |
|
$0.23M |
|
$5.46M |
|
$1.77M |
|
-- |
|
-- |
|
$1.77M |
|
$3.69M |
|
$3.69M |
|
$3.69M |
|
8.05M |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.96 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-137.28% |
|
|
Return on Tangible Equity |
-137.28% |
-92.78% |
|
-137.28% |
|
$0.46 |
|
-- |
|
-- |
|